.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The final overall-survival analysis of the FLAURA trial established osimertinib as a major first-line option for patients with advanced non-small-cell lung cancer harboring sensitizing EGFR mutations. In previously untreated patients, osimertinib produced a longer median overall survival than standard first-generation EGFR tyrosine kinase inhibitors. The survival benefit was achieved while maintaining a broadly comparable overall safety profile, despite longer treatment exposure. For HCPs, the study demonstrates the clinical importance of obtaining molecular results before selecting systemic therapy in appropriate advanced NSCLC. It also shows how treatment sequencing has evolved: targeted therapy can be selected up front when a relevant driver alteration is identified, rather than relying solely on histology and clinical stage. This fits the NAPCON lung-cancer sessions on biomarker testing and access to modern staging and treatment pathways. The paper should not be generalized to EGFR-negative disease, but it provides a clear example of how biomarker-driven treatment can change outcomes in a defined molecular subgroup. In multidisciplinary practice, the result reinforces the value of coordinated pathology, molecular testing, imaging and oncology decision-making.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The final overall-survival analysis of the FLAURA trial established osimertinib as a major first-line option for patients with advanced non-small-cell lung cancer harboring sensitizing EGFR mutations. In previously untreated patients, osimertinib produced a longer median overall survival than standard first-generation EGFR tyrosine kinase inhibitors. The survival benefit was achieved while maintaining a broadly comparable overall safety profile, despite longer treatment exposure. For HCPs, the study demonstrates the clinical importance of obtaining molecular results before selecting systemic therapy in appropriate advanced NSCLC. It also shows how treatment sequencing has evolved: targeted therapy can be selected up front when a relevant driver alteration is identified, rather than relying solely on histology and clinical stage. This fits the NAPCON lung-cancer sessions on biomarker testing and access to modern staging and treatment pathways. The paper should not be generalized to EGFR-negative disease, but it provides a clear example of how biomarker-driven treatment can change outcomes in a defined molecular subgroup. In multidisciplinary practice, the result reinforces the value of coordinated pathology, molecular testing, imaging and oncology decision-making.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
